|
MechanismHMG-CoA reductase inhibitors [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date30 Jan 2004 |
/ CompletedNot Applicable NON INTERVENTIONAL STUDY (NIS) IN PATIENTS WITH BIPOLAR DISCORDER (MANIC OR MIXED EPISODES) AND SCHIZOPHRENIA UNDERGOING TREATEMENT WITH ZELDOX
Investigation of the impact of Zeldox on metabolic parametres in patients with bipolar disorder or with schizophrenia and impact of the treatment for the quality of life
100 Clinical Results associated with Viatris Pharmaceuticals Co., Ltd.
0 Patents (Medical) associated with Viatris Pharmaceuticals Co., Ltd.
100 Deals associated with Viatris Pharmaceuticals Co., Ltd.
100 Translational Medicine associated with Viatris Pharmaceuticals Co., Ltd.